SI9720020B - Human antibodies that bind human TNF alpha - Google Patents

Human antibodies that bind human TNF alpha Download PDF

Info

Publication number: SI9720020B
Authority: SI; Slovenia
Prior art keywords: seq; antibody; amino acid; antigen; acid sequence
Prior art date: 1996-02-09

Application number

SI9720020A

Other languages

English (en)

Slovenian (sl)

Other versions

SI9720020A (sl

Inventor

Jochen G Salfeld

Deborah J Allen

Zehra Kaymakcalan

Boris Labkovsky

John A Mankovich

Brian T Mcguinness

Andrew J Roberts

Paul Sakorafas

Hendricus R J M Hoogenboom

David Schoenhaut

Tristan J Vaughan

Michael White

Alison J Wilton

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-09

Filing date

1997-02-10

Publication date

2001-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26707297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9720020(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-02-09 Priority claimed from US08/599,226 external-priority patent/US6090382A/en

1997-02-10 Application filed by Basf Ag filed Critical Basf Ag

1999-10-31 Publication of SI9720020A publication Critical patent/SI9720020A/sl

2001-12-31 Publication of SI9720020B publication Critical patent/SI9720020B/sl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Virology (AREA)
Oncology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)

SI9720020A 1996-02-09 1997-02-10 Human antibodies that bind human TNF alpha SI9720020B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/599,226 US6090382A (en)	1996-02-09	1996-02-09	Human antibodies that bind human TNFα
US3147696P	1996-11-25	1996-11-25
PCT/US1997/002219 WO1997029131A1 (en)	1996-02-09	1997-02-10	HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)

Publications (2)

Publication Number	Publication Date
SI9720020A SI9720020A (sl)	1999-10-31
SI9720020B true SI9720020B (en)	2001-12-31

Family

ID=26707297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9720020A SI9720020B (en)	1996-02-09	1997-02-10	Human antibodies that bind human TNF alpha

Country Status (32)

Country	Link
US (9)	US6258562B1 (cs)
EP (1)	EP0929578B1 (cs)
JP (8)	JP3861118B2 (cs)
KR (1)	KR100317188B1 (cs)
CN (5)	CN102070715A (cs)
AT (1)	ATE239041T1 (cs)
AU (1)	AU722077B2 (cs)
BG (7)	BG64776B1 (cs)
BR (3)	BRPI9707379B8 (cs)
CA (1)	CA2243459C (cs)
CY (2)	CY2463B1 (cs)
CZ (1)	CZ292465B6 (cs)
DE (4)	DE122004000003I1 (cs)
DK (1)	DK0929578T3 (cs)
ES (1)	ES2198552T3 (cs)
HK (4)	HK1214609A1 (cs)
HU (4)	HU230515B1 (cs)
IL (4)	IL125697A (cs)
LU (1)	LU91062I2 (cs)
MX (1)	MX336813B (cs)
NL (1)	NL300143I2 (cs)
NO (6)	NO316711B1 (cs)
NZ (5)	NZ576716A (cs)
PL (2)	PL188192B1 (cs)
PT (1)	PT929578E (cs)
RO (2)	RO123028B1 (cs)
RU (3)	RU2270030C2 (cs)
SI (1)	SI9720020B (cs)
SK (1)	SK284040B6 (cs)
TR (1)	TR199801532T2 (cs)
UA (2)	UA57726C2 (cs)
WO (1)	WO1997029131A1 (cs)

Families Citing this family (481)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030225254A1 (en) *	1989-08-07	2003-12-04	Rathjen Deborah Ann	Tumour necrosis factor binding ligands
US5959087A (en) *	1989-08-07	1999-09-28	Peptide Technology, Ltd.	Tumour necrosis factor binding ligands
JP3443119B2 (ja) *	1989-08-07	2003-09-02	ペプテックリミテッド	腫瘍壊死因子結合リガンド
US7192584B2 (en)	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US6270766B1 (en)	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
ZA95960B (en) *	1994-03-14	1995-10-10	Genetics Inst	Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6706264B1 (en)	1994-03-14	2004-03-16	Genetics Institute, Llc	Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US20010055581A1 (en)	1994-03-18	2001-12-27	Lawrence Tamarkin	Composition and method for delivery of biologically-active factors
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
MX336813B (es) *	1996-02-09	2016-02-02	Abbvie Biotechnology Ltd	Anticuerpos humanos que ligan el tnfa humano.
US7129061B1 (en) *	1996-08-07	2006-10-31	Biogen Idec Ma Inc.	Tumor necrosis factor related ligand
US20040009166A1 (en) *	1997-04-30	2004-01-15	Filpula David R.	Single chain antigen-binding polypeptides for polymer conjugation
EP0979102A4 (en)	1997-04-30	2005-11-23	Enzon Inc	DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US6407218B1 (en)	1997-11-10	2002-06-18	Cytimmune Sciences, Inc.	Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en)	2001-04-30	2007-06-12	Cytimmune Sciences, Inc.	Colloidal metal compositions and methods
US7067144B2 (en) *	1998-10-20	2006-06-27	Omeros Corporation	Compositions and methods for systemic inhibition of cartilage degradation
MXPA01006006A (es)	1998-12-14	2004-08-12	Genetics Inst	Cadena receptora de citocina.
US7553487B2 (en)	1998-12-14	2009-06-30	Genetics Institute, Llc	Method and compositions for treating asthma
JP2002538170A (ja) *	1999-03-02	2002-11-12	セントコール，インコーポレイテッド	喘息の治療における抗−ＴＮＦα抗体
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
US20040220103A1 (en)	1999-04-19	2004-11-04	Immunex Corporation	Soluble tumor necrosis factor receptor treatment of medical disorders
MXPA02003420A (es) *	1999-10-06	2002-08-20	Basf Ag	Inhibidores de la via de senalizacion de endotelina y antagonistas de los receptores de alfav°3 integrina para el tratamiento en combinacion.
CA2399148A1 (en)	2000-02-10	2001-08-16	Abbott Laboratories	Antibodies that bind human interleukin-18 and methods of making and using
GB0013810D0 (en)	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
KR100919593B1 (ko)	2000-06-29	2009-09-29	아보트 러보러터리즈	이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20050196755A1 (en) *	2000-11-17	2005-09-08	Maurice Zauderer	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7981420B2 (en)	2000-12-22	2011-07-19	Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V.	Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
US6919183B2 (en) *	2001-01-16	2005-07-19	Regeneron Pharmaceuticals, Inc.	Isolating cells expressing secreted proteins
US20090137416A1 (en)	2001-01-16	2009-05-28	Regeneron Pharmaceuticals, Inc.	Isolating Cells Expressing Secreted Proteins
WO2002076196A1 (en)	2001-03-22	2002-10-03	Abbott Gmbh & Co. Kg	Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US6410955B1 (en) *	2001-04-19	2002-06-25	Micron Technology, Inc.	Comb-shaped capacitor for use in integrated circuits
CA2817619A1 (en)	2001-06-08	2002-12-08	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
EP2295081B1 (en)	2001-06-26	2018-10-31	Amgen Inc.	Antibodies to OPGL
WO2003002187A2 (en) *	2001-06-26	2003-01-09	Photomed Technologies, Inc.	Multiple wavelength illuminator
US20050271663A1 (en) *	2001-06-28	2005-12-08	Domantis Limited	Compositions and methods for treating inflammatory disorders
TWI334439B (en)	2001-08-01	2010-12-11	Centocor Inc	Anti-tnf antibodies, compositions, methods and uses
AU2002341766A1 (en) *	2001-09-20	2003-04-01	Genstar Therapeutics Corporation	Improved methods for treatment with viral vectors
US20030065382A1 (en) *	2001-10-02	2003-04-03	Fischell Robert E.	Means and method for the treatment of coronary artery obstructions
ES2629395T3 (es)	2001-10-04	2017-08-09	Genetics Institute, Llc	Métodos y composiciones para modular la actividad de la interleucina-21
US20040018195A1 (en) *	2002-03-26	2004-01-29	Griswold Don Edgar	Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US20040009172A1 (en) *	2002-04-26	2004-01-15	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) *	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
WO2004009776A2 (en)	2002-07-19	2004-01-29	Abbott Biotechnology Ltd.	TREATMENT OF TNFα RELATED DISORDERS
US20090280065A1 (en) *	2006-04-10	2009-11-12	Willian Mary K	Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
US20040091490A1 (en) *	2002-08-28	2004-05-13	Robert Johnson	Stable pH optimized formulation of a modified antibody
MY150740A (en)	2002-10-24	2014-02-28	Abbvie Biotechnology Ltd	Low dose methods for treating disorders in which tnf? activity is detrimental
US20060034845A1 (en)	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
WO2004041863A2 (en) *	2002-11-08	2004-05-21	Ablynx N.V.	Single domain antibodies directed against interferon- gamma and uses therefor
EP1900753B1 (en)	2002-11-08	2017-08-09	Ablynx N.V.	Method of administering therapeutic polypeptides, and polypeptides therefor
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20040162414A1 (en) *	2002-11-22	2004-08-19	Santora Ling C.	Method for reducing or preventing modification of a polypeptide in solution
US20040101939A1 (en) *	2002-11-22	2004-05-27	Santora Ling C.	Method for reducing or preventing modification of a polypeptide in solution
US7285269B2 (en)	2002-12-02	2007-10-23	Amgen Fremont, Inc.	Antibodies directed to tumor necrosis factor
WO2004060911A2 (en) *	2002-12-30	2004-07-22	Amgen Inc.	Combination therapy with co-stimulatory factors
US7101978B2 (en) *	2003-01-08	2006-09-05	Applied Molecular Evolution	TNF-α binding molecules
JP2007525409A (ja) *	2003-01-08	2007-09-06	アプライドモレキュラーエボリューション，インコーポレイテッド	ＴＮＦ−α結合分子
JP2006517789A (ja) *	2003-01-10	2006-08-03	アブリンクスエン．ヴェー．	治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
NZ542306A (en) *	2003-03-14	2008-04-30	Wyeth Corp	Antibodies against human IL-21 receptor and uses therefor
EP1460088A1 (en)	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
WO2004098578A2 (en) *	2003-05-12	2004-11-18	Altana Pharma Ag	Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
FR2856075B1 (fr) *	2003-06-16	2007-10-12	Monoclonal Antibodies Therapeu	Procede essentiellement automatise de criblage a grande echelle de cellules secretant des anticorps monoclonaux
FR2859725B1 (fr) *	2003-09-16	2006-03-10	Neovacs	Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US20050100965A1 (en)	2003-11-12	2005-05-12	Tariq Ghayur	IL-18 binding proteins
KR100772800B1 (ko) *	2003-11-17	2007-11-01	주식회사유한양행	인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US20050175583A1 (en)	2003-12-02	2005-08-11	Lawrence Tamarkin	Methods and compositions for the production of monoclonal antibodies
PL3718564T3 (pl)	2003-12-23	2024-03-18	Genentech, Inc.	Nowe przeciwciała anty-IL 13 i ich zastosowania
US7435799B2 (en) *	2004-01-08	2008-10-14	Applied Molecular Evolution	TNF-α binding molecules
US7625549B2 (en) *	2004-03-19	2009-12-01	Amgen Fremont Inc.	Determining the risk of human anti-human antibodies in transgenic mice
US20050260679A1 (en) *	2004-03-19	2005-11-24	Sirid-Aimee Kellerman	Reducing the risk of human anti-human antibodies through V gene manipulation
TW201705980A (zh)	2004-04-09	2017-02-16	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN100427504C (zh) *	2004-06-02	2008-10-22	北京天广实生物技术有限公司	TNFα高亲和力嵌合抗体及其用途
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
RU2007102287A (ru) *	2004-08-05	2008-09-10	Вайет (Us)	Антагонисты активности рецептора интерлейкина-21
WO2006041970A2 (en) *	2004-10-08	2006-04-20	Abbott Biotechnology Ltd.	Treatment of respiratory syncytial virus (rsv) infection
CN101048426A (zh) *	2004-10-22	2007-10-03	金克克国际有限公司	分离人抗体
CA2587597A1 (en)	2004-11-19	2006-05-26	Biogen Idec Ma Inc.	Treatment for multiple sclerosis
TR201901929T4 (tr)	2005-02-08	2019-03-21	Genzyme Corp	TGFBeta'ya antikorlar.
GT200600065A (es) *	2005-02-14	2006-10-02		Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
CN101160528A (zh) *	2005-02-14	2008-04-09	惠氏公司	Il17-f在诊断和治疗气道炎症中的用途
WO2006089095A2 (en)	2005-02-17	2006-08-24	Biogen Idec Ma Inc.	Treating neurological disorders
GT200600148A (es) *	2005-04-14	2006-11-22		Metodos para el tratamiento y la prevencion de fibrosis
CA2607697C (en)	2005-05-10	2015-01-06	Biogen Idec Ma Inc.	Treating and evaluating inflammatory disorders
NZ595225A (en) *	2005-05-16	2013-05-31	Abbott Biotech Ltd	Use of tnf inhibitor for treatment of erosive polyarthritis
AU2012254978C1 (en) *	2005-05-16	2017-06-01	Abbvie Biotechnology Ltd	Use of TNF inhibitor for treatment of erosive polyarthritis
WO2006133287A2 (en) *	2005-06-06	2006-12-14	Wyeth	Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
KR101457223B1 (ko)	2005-06-07	2014-11-04	에스바테크 - 어 노바티스 컴파니 엘엘씨	ＴＮＦα를 억제하는 안정적이고 가용성인 항체
BRPI0611901A2 (pt)	2005-06-14	2012-08-28	Amgen, Inc	composição, liofilizado, kit, e, processo para preparar uma composição
US20060286108A1 (en) *	2005-06-16	2006-12-21	Bell Katherine A	Topical compositions for the treatment of chronic wounds
WO2006138690A2 (en) *	2005-06-17	2006-12-28	Abbott Laboratories	Improved method of treating degenerative spinal disorders
EP2664340B1 (en) *	2005-06-24	2020-02-12	Duke University	A direct drug delivery system based on thermally responsive biopolymers
MX2008000985A (es)	2005-07-21	2008-04-07	Abbott Lab	Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
TW200726776A (en) *	2005-07-29	2007-07-16	Friedrich Alexander University Of Erlangen Nuremberg	CD33-specific single-chain immunotoxin and methods of use
NZ612578A (en)	2005-08-19	2014-11-28	Abbvie Inc	Dual variable domain immunoglobin and uses thereof
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
EP2500355A3 (en)	2005-08-19	2012-10-24	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) *	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP1928905B1 (de)	2005-09-30	2015-04-15	AbbVie Deutschland GmbH & Co KG	Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
WO2007049286A1 (en) *	2005-10-27	2007-05-03	Tata Memorial Centre	A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma
CN103336129A (zh)	2005-11-01	2013-10-02	阿布维生物技术有限公司	使用生物标志物诊断强直性脊柱炎的方法和组合物
TW200736277A (en)	2005-11-14	2007-10-01	Amgen Inc	RANKL antibody-PTH/PTHrP chimeric molecules
US8691224B2 (en)	2005-11-30	2014-04-08	Abbvie Inc.	Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr)	2005-11-30	2017-02-24	Abbvie Inc.	Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
WO2007073486A2 (en)	2005-12-20	2007-06-28	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) *	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US7846439B2 (en)	2006-02-01	2010-12-07	Cephalon Australia Pty Ltd	Domain antibody construct
TW200744634A (en)	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
CN102887955A (zh)	2006-04-05	2013-01-23	艾博特生物技术有限公司	抗体纯化
US9605064B2 (en)	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
US9399061B2 (en)	2006-04-10	2016-07-26	Abbvie Biotechnology Ltd	Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
CA2564435A1 (en)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methods for monitoring and treating intestinal disorders
US20080118496A1 (en) *	2006-04-10	2008-05-22	Medich John R	Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2666479A3 (en)	2006-04-10	2014-03-26	Abbott Biotechnology Ltd	Uses and compositions for treatment of juvenile rheumatoid arthritis
US20090317399A1 (en) *	2006-04-10	2009-12-24	Pollack Paul F	Uses and compositions for treatment of CROHN'S disease
WO2007120626A2 (en) *	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Uses and compositions for treatment of ankylosing spondylitis
WO2008063213A2 (en)	2006-04-10	2008-05-29	Abbott Biotechnology Ltd.	Uses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en) *	2006-04-19	2008-06-05	Medich John R	Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) *	2006-06-08	2008-12-18	Hoffman Rebecca S	Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en)	2006-06-08	2010-01-28	Wong Robert L	Uses and compositions for treatment of ankylosing spondylitis
MX2008016335A (es)	2006-06-30	2009-01-21	Abbott Biotech Ltd	Dispositivo automatico de inyeccion.
JP2010502224A (ja)	2006-09-08	2010-01-28	アボット・ラボラトリーズ	インターロイキン１３結合タンパク質
US8911964B2 (en)	2006-09-13	2014-12-16	Abbvie Inc.	Fed-batch method of making human anti-TNF-alpha antibody
EP2500416A1 (en)	2006-09-13	2012-09-19	Abbott Laboratories	Cell culture improvements
AU2007294731B2 (en)	2006-09-13	2014-04-17	Abbvie Inc.	Cell culture improvements
ES2442258T3 (es)	2006-10-27	2014-02-10	Abbvie Biotechnology Ltd	Anticuerpos cristalinos anti-hTNF alfa
CN101534824A (zh)	2006-11-17	2009-09-16	艾博特公司	作为化学活素受体拮抗剂的氨基吡咯烷
EP2101780B1 (en)	2006-11-21	2013-10-09	Kalobios Pharmaceuticals, Inc.	Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2114443A4 (en)	2006-12-29	2011-08-10	Abbott Lab	IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
KR20090100461A (ko) *	2007-01-16	2009-09-23	아보트 러보러터리즈	건선의 치료방법
JP2008209378A (ja) *	2007-01-31	2008-09-11	Fujifilm Corp	バイオセンサー基板
HUE026001T2 (en)	2007-02-05	2016-04-28	Apellis Pharmaceuticals Inc	Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
RU2009137582A (ru) *	2007-03-12	2011-04-20	Эсбатек Аг (Ch)	Инженерия и оптимизация одноцепочечных антител на основе последовательности
TW200902064A (en) *	2007-03-28	2009-01-16	Wyeth Corp	Methods and compositions for modulating IL-17F/IL-17A biological activity
US7807168B2 (en) *	2007-04-10	2010-10-05	Vaccinex, Inc.	Selection of human TNFα specific antibodies
WO2008124858A2 (en) *	2007-04-11	2008-10-23	F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H.	Targeted receptor
WO2008150491A2 (en)	2007-05-31	2008-12-11	Abbott Laboratories	BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
EP2152318A4 (en) *	2007-06-01	2011-12-07	Abbott Biotech Ltd	COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
JP2010528647A (ja) *	2007-06-06	2010-08-26	ドマンティスリミテッド	ポリペプチド、抗体可変ドメインおよびアンタゴニスト
CA2688433A1 (en) *	2007-06-06	2008-12-11	Domantis Limited	Methods for selecting protease resistant polypeptides
WO2008154543A2 (en)	2007-06-11	2008-12-18	Abbott Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis
NZ595526A (en) *	2007-06-14	2013-03-28	Biogen Idec Inc	Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
EP2164961B1 (en) *	2007-06-25	2015-01-07	ESBATech, an Alcon Biomedical Research Unit LLC	Sequence based engineering and optimization of single chain antibodies
BRPI0813645A2 (pt)	2007-06-25	2014-12-30	Esbatech Alcon Biomed Res Unit	Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
JP2010533181A (ja) *	2007-07-13	2010-10-21	アボツト・バイオテクノロジー・リミテツド	ＴＮＦα阻害剤の肺投与のための方法及び組成物
WO2009020654A1 (en)	2007-08-08	2009-02-12	Abbott Laboratories	Compositions and methods for crystallizing antibodies
US20090304719A1 (en)	2007-08-22	2009-12-10	Patrick Daugherty	Activatable binding polypeptides and methods of identification and use thereof
US8969024B2 (en)	2007-08-28	2015-03-03	Abbvie Biotechnology Ltd	Compositions and methods comprising binding proteins for adalimumab
JP2009082033A (ja) *	2007-09-28	2009-04-23	Kaneka Corp	完全ヒト型抗体生産法
MX2010003371A (es)	2007-09-28	2010-05-05	Intrexon Corp	Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
CA2706700A1 (en)	2007-11-08	2009-05-14	Cytimmune Sciences, Inc.	Compositions and methods for generating antibodies
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
US8420081B2 (en)	2007-11-30	2013-04-16	Abbvie, Inc.	Antibody formulations and methods of making same
US20090271164A1 (en) *	2008-01-03	2009-10-29	Peng Joanna Z	Predicting long-term efficacy of a compound in the treatment of psoriasis
CA2711984A1 (en)	2008-01-15	2009-07-23	Abbott Gmbh & Co. Kg	Powdered protein compositions and methods of making same
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
RU2540013C2 (ru)	2008-03-13	2015-01-27	Биотест Аг	Средство для лечения заболевания
EP2260057B1 (en)	2008-03-13	2016-11-23	Biotest AG	Anti-CD4 antibody dosage regimen for treating autoimmune disease
EP2265643B1 (en)	2008-03-13	2016-10-19	Biotest AG	Dosing regimen for treating psoriasis and rheumatoid arthritis
WO2009117289A2 (en)	2008-03-18	2009-09-24	Abbott Laboratories	Methods for treating psoriasis
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
SG190572A1 (en)	2008-04-29	2013-06-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
EP2113568A1 (en)	2008-04-30	2009-11-04	Deutsches Rheuma-Forschungszentrum Berlin	Knock-in mouse for modelling blockade of human TNFalpha
EP2116556B1 (en)	2008-05-09	2016-03-23	AbbVie Deutschland GmbH & Co KG	Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
EP2311493A4 (en) *	2008-05-20	2012-09-26	Kaneka Corp	CYTOTOXIC COMPOSITION
CA2726087A1 (en)	2008-06-03	2009-12-10	Tariq Ghayur	Dual variable domain immunoglobulins and uses thereof
TW201006485A (en)	2008-06-03	2010-02-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CA2728829C (en)	2008-06-25	2018-01-02	Esbatech, An Alcon Biomedical Research Unit Llc	Solubility optimization of immunobinders
KR102050040B1 (ko)	2008-06-25	2019-11-28	에스바테크 - 어 노바티스 컴파니 엘엘씨	ＴＮＦα를 저해하는 안정한 가용성 항체
BRPI0914251B1 (pt)	2008-06-25	2022-07-19	Novartis Ag	Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
CN102131516B (zh)	2008-06-27	2016-03-16	杜克大学	包含弹性蛋白样肽的治疗剂
NZ590667A (en) *	2008-07-02	2013-01-25	Emergent Product Dev Seattle	Tgf-b antagonist multi-target binding proteins
TW201014602A (en)	2008-07-08	2010-04-16	Abbott Lab	Prostaglandin E2 binding proteins and uses thereof
CN102149825B (zh)	2008-07-08	2015-07-22	Abbvie公司	前列腺素e2双重可变结构域免疫球蛋白及其用途
KR20110048536A (ko) *	2008-08-28	2011-05-11	와이어쓰 엘엘씨	자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
JP5860699B2 (ja) *	2008-10-07	2016-02-16	ナショナルチェンクンユニバーシティ	骨粗鬆症の治療のためのｉｌ−２０アンタゴニストの使用
CA2738243C (en)	2008-10-29	2020-09-29	Wyeth Llc	Formulations of single domain antigen binding molecules
BRPI0919879A2 (pt)	2008-10-29	2016-02-16	Wyeth Llc	métodos para purificação de moléculas de ligação a antígeno de domínio único
US8415291B2 (en)	2008-10-31	2013-04-09	Centocor Ortho Biotech Inc.	Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
CN101419224B (zh) *	2008-11-06	2012-08-22	复旦大学附属华山医院	一种同时测定人血浆中霉酚酸酯、霉酚酸及其代谢物的方法
RU2011126338A (ru) *	2008-11-28	2013-01-10	Эбботт Лэборетриз	Стабильные композиции антител и способы их стабилизации
CN101766602B (zh) *	2008-12-30	2012-01-11	中国医学科学院血液病医院（血液学研究所）	取代芳香基腙类化合物在作为肿瘤坏死因子抑制剂药物方面的应用
US20110251099A1 (en)	2008-12-30	2011-10-13	Sudha Visvanathan	SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
RU2636046C2 (ru)	2009-01-12	2017-11-17	Сайтомкс Терапьютикс, Инк	Композиции модифицированных антител, способы их получения и применения
AU2010215761B2 (en)	2009-02-23	2017-04-06	Cytomx Therapeutics, Inc	Proproteins and methods of use thereof
US8030026B2 (en)	2009-02-24	2011-10-04	Abbott Laboratories	Antibodies to troponin I and methods of use thereof
TWI541021B (zh) *	2009-03-05	2016-07-11	艾伯維有限公司	Ｉｌ－１７結合蛋白
PE20120835A1 (es) *	2009-04-16	2012-07-23	Abbvie Biotherapeutics Inc	Anticuerpos anti-tnf-alfa y sus usos
CN101875694B (zh) *	2009-04-28	2014-04-02	中国医学科学院基础医学研究所	TNFα的抗体及其用途
WO2010127146A1 (en)	2009-04-29	2010-11-04	Abbott Biotechnology Ltd	Automatic injection device
US20100278822A1 (en) *	2009-05-04	2010-11-04	Abbott Biotechnology, Ltd.	Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2010132872A1 (en) *	2009-05-15	2010-11-18	Novimmune S.A	Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
UY32808A (es) *	2009-07-29	2011-02-28	Abbott Lab	Inmunoglobulinas como dominio variable dual y usos de las mismas
US9029505B2 (en) *	2009-08-14	2015-05-12	Phasebio Pharmaceuticals, Inc.	Modified vasoactive intestinal peptides
NZ625850A (en) *	2009-08-21	2015-12-24	Gilead Biologics Inc	Methods and compositions for treatment of pulmonary fibrotic disorders
BR112012004546A8 (pt)	2009-08-29	2017-12-05	Abbott Lab	Terapêutica por proteínas ligantes dll4-ligantes
WO2011028811A2 (en)	2009-09-01	2011-03-10	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
SG179135A1 (en) *	2009-09-14	2012-05-30	Abbott Lab	Methods for treating psoriasis
CN102573895A (zh) *	2009-09-24	2012-07-11	埃克斯生物科技公司	减少抗-抗体反应的方法、组合物和试剂盒
EP2480888B1 (en)	2009-09-25	2016-11-30	XOMA Technology Ltd.	Screening methods
US8926976B2 (en)	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
BR112012008833A2 (pt)	2009-10-15	2015-09-08	Abbott Lab	imunoglobulinas de dominio variavel duplo e usos das mesmas
JP5697677B2 (ja) *	2009-10-26	2015-04-08	ネステクソシエテアノニム	抗ｔｎｆ薬及び自己抗体の検出用アッセイ
UY32979A (es) *	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053699A1 (en)	2009-10-30	2011-05-05	Abbott Laboratories	Sorf constructs and multiple gene expression
WO2011053707A1 (en)	2009-10-31	2011-05-05	Abbott Laboratories	Antibodies to receptor for advanced glycation end products (rage) and uses thereof
WO2011058087A1 (en)	2009-11-11	2011-05-19	Gentian As	Immunoassay for assessing related analytes of different origin
GB0920944D0 (en)	2009-11-30	2010-01-13	Biotest Ag	Agents for treating disease
WO2011068927A2 (en) *	2009-12-04	2011-06-09	Abbott Laboratories	11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
MX2012006560A (es)	2009-12-08	2012-10-05	Abbott Gmbh & Co Kg	Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
RU2582401C2 (ru)	2009-12-15	2016-04-27	Эббви Байотекнолоджи Лтд	Усовершенствованная пусковая кнопка для автоматического инъекционного устройства
US20110150891A1 (en) *	2009-12-16	2011-06-23	Philip Bosch	Methods of Treating Interstitial Cystitis
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US9096655B2 (en)	2010-01-27	2015-08-04	Tata Memorial Centre	Method for in-vivo binding of chromatin fragments
JP2013518590A (ja)	2010-02-02	2013-05-23	アボツト・バイオテクノロジー・リミテツド	ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
CN102167741B (zh) *	2010-02-25	2014-05-14	上海百迈博制药有限公司	一种全人源抗TNF-α单克隆抗体、其制备方法及用途
KR101853278B1 (ko)	2010-03-02	2018-05-02	애브비 인코포레이티드	치료학적 ｄｌｌ４ 결합 단백질
ES2993140T3 (en)	2010-04-02	2024-12-23	Amunix Pharmaceuticals Inc	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
KR20130010123A (ko)	2010-04-07	2013-01-25	아비에 인코포레이티드	ＴＮＦ-α 결합 단백질
US8987419B2 (en)	2010-04-15	2015-03-24	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
HRP20171045T1 (hr)	2010-04-16	2017-10-06	Biogen Ma Inc.	Protutijela anti-vla-4
JP5809242B2 (ja)	2010-04-21	2015-11-10	アッヴィバイオテクノロジーリミテッド	治療薬の制御送達のための装着型自動注入装置
AR081246A1 (es)	2010-05-14	2012-07-18	Abbott Lab	Proteinas de union a il-1
WO2011146727A1 (en)	2010-05-19	2011-11-24	Philip Bosch	Methods of treating interstitial cystitis
EP2575884B1 (en)	2010-06-03	2018-07-18	AbbVie Biotechnology Ltd	Uses and compositions for treatment of hidradenitis suppurativa (hs)
WO2012006500A2 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012009705A1 (en)	2010-07-15	2012-01-19	Zyngenia, Inc.	Ang-2 binding complexes and uses thereof
EP3252072A3 (en)	2010-08-03	2018-03-14	AbbVie Inc.	Dual variable domain immunoglobulins and uses thereof
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
WO2012024650A2 (en)	2010-08-19	2012-02-23	Abbott Laboratories	Anti-ngf antibodies and their use
JP2013539364A (ja)	2010-08-26	2013-10-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリンおよびその使用
UY33679A (es)	2010-10-22	2012-03-30	Esbatech	Anticuerpos estables y solubles
CA3152557A1 (en)	2010-10-29	2012-05-03	Abbvie Inc.	Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx)	2010-10-29	2017-02-10		Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
MX2013004979A (es) *	2010-11-02	2013-07-30	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
US8821865B2 (en)	2010-11-11	2014-09-02	Abbvie Biotechnology Ltd.	High concentration anti-TNFα antibody liquid formulations
ES2603129T3 (es)	2010-11-23	2017-02-23	Abbvie Ireland Unlimited Company	Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
PT2643322T (pt)	2010-11-23	2017-11-13	Abbvie Inc	Sais e formas cristalinas de um agente indutor de apoptose
AR084210A1 (es) *	2010-12-08	2013-05-02	Abbott Lab	PROTEINAS DE UNION AL TNF-a
PE20141060A1 (es)	2010-12-21	2014-09-26	Abbvie Inc	Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
TW201307388A (zh)	2010-12-21	2013-02-16	Abbott Lab	Ｉｌ－１結合蛋白
EP2490024A1 (en)	2010-12-22	2012-08-22	Proteomika, S.L.	Method to optimize the treatment of patients with biological drugs
CN103491998B (zh)	2011-01-24	2015-11-25	爱康医学农业合作协会有限公司	注射器
UA112308C2 (uk)	2011-01-24	2016-08-25	Еббві Байотекнолоджи Лтд.	Знімання кожухів голки зі шприців і автоматичних ін'єкційних пристроїв
RU2727040C2 (ru)	2011-01-24	2020-07-17	Эббви Байотекнолоджи Лтд.	Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
RU2455025C1 (ru) *	2011-02-10	2012-07-10	Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ")	Способ фармакологической коррекции ишемии конечности смесью растворов гомеопатических разведений
US20130344081A1 (en)	2011-03-07	2013-12-26	The University Of Tokushima	Method of treating amyotrophic lateral sclerosis
CA2829773A1 (en)	2011-03-18	2012-09-27	Abbvie Inc.	Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof
TWI743461B (zh)	2011-03-28	2021-10-21	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX2013011263A (es)	2011-03-29	2014-03-27	Abbvie Inc	Despliegue de cubierta mejorado en dispositivos de inyeccion automaticos.
ES2605817T3 (es)	2011-04-21	2017-03-16	Abbvie Inc.	Dispositivo de inyección automático portátil
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2714738B1 (en)	2011-05-24	2018-10-10	Zyngenia, Inc.	Multivalent and monovalent multispecific complexes and their uses
DK2715352T3 (da)	2011-05-31	2019-05-20	Biogen Ma Inc	Fremgangsmåde til vurdering af risiko for pml
CA2873553C (en)	2011-06-06	2020-01-28	Phasebio Pharmaceuticals, Inc.	Use of modified vasoactive intestinal peptides in the treatment of hypertension
SG10201505454SA (en)	2011-07-13	2015-09-29	Abbvie Inc	Methods and compositions for treating asthma using anti-il-13 antibodies
GB201112429D0 (en) *	2011-07-19	2011-08-31	Glaxo Group Ltd	Antigen-binding proteins with increased FcRn binding
CN103917555A (zh) *	2011-08-01	2014-07-09	艾瓦夏生物制剂公司	人tnf特异性的牛科动物多克隆抗体
CA2850572A1 (en) *	2011-10-20	2013-04-25	Esbatech, A Novartis Company Llc	Stable multiple antigen-binding antibody
RU2014121043A (ru)	2011-10-24	2015-12-10	Эббви Инк.	Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
PE20141545A1 (es) *	2011-10-24	2014-11-26	Abbvie Inc	Inmunoenlazadores dirigidos contra el tnf
HK1200322A1 (en)	2011-10-24	2015-08-07	Abbvie Inc.	Immunobinders directed against sclerostin
EP2786156A2 (en)	2011-11-30	2014-10-08	AbbVie Deutschland GmbH & Co KG	Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
CA2855570A1 (en)	2011-12-14	2013-06-20	AbbVie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
CA3204283A1 (en)	2011-12-14	2013-06-20	AbbVie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
EP2791170A1 (en)	2011-12-16	2014-10-22	Synthon Biopharmaceuticals B.V.	Compounds and methods for treating inflammatory diseases
UY34556A (es)	2011-12-30	2013-07-31	Abbvie Inc	Dominio variable dual de inmunoglobulinas y sus usos
TW201333035A (zh)	2011-12-30	2013-08-16	Abbvie Inc	針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
EP3369746A1 (en)	2012-01-27	2018-09-05	AbbVie Deutschland GmbH & Co KG	Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
JP2015509526A (ja)	2012-03-07	2015-03-30	カディラヘルスケアリミティド	医薬製剤
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
WO2013158279A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Protein purification methods to reduce acidic species
EP2657334B1 (en)	2012-04-26	2016-07-06	GeneFrontier Corporation	Efficient method for displaying protein multimer
WO2013176754A1 (en)	2012-05-24	2013-11-28	Abbvie Inc.	Novel purification of antibodies using hydrophobic interaction chromatography
CA2875783C (en)	2012-06-06	2018-12-11	Zoetis Llc	Caninized anti-ngf antibodies and methods thereof
EP2859017B1 (en)	2012-06-08	2019-02-20	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
EP2890402B1 (en)	2012-08-31	2019-04-17	Sutro Biopharma, Inc.	Modified amino acids comprising an azido group
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
HK1211981A1 (en)	2012-09-02	2016-06-03	Abbvie Inc.	Methods to control protein heterogeneity
PE20150964A1 (es)	2012-09-07	2015-07-25	Coherus Biosciences Inc	Formulaciones acuosas estables de adalimumab
KR20150056788A (ko) *	2012-09-19	2015-05-27	애브비 바이오테라퓨틱스 인크.	면역원성이 감소된 항체의 동정 방법
TW202037609A (zh)	2012-11-01	2020-10-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
CN105431453A (zh)	2012-11-01	2016-03-23	艾伯维公司	稳定的双重可变结构域免疫球蛋白制剂
TW202423993A (zh)	2012-11-14	2024-06-16	美商再生元醫藥公司	重組細胞表面捕捉蛋白質
US9550986B2 (en)	2012-12-21	2017-01-24	Abbvie Inc.	High-throughput antibody humanization
US9856319B2 (en)	2012-12-28	2018-01-02	Abbvie Inc.	Monovalent binding proteins
EP2938634A2 (en)	2012-12-28	2015-11-04	AbbVie Inc.	Dual specific binding proteins having a receptor sequence
JP6134392B2 (ja)	2013-01-25	2017-05-24	サイモン・エルエルシー	循環している生物学的に活性な可溶性ｔｎｆの選択的低減用の組成物およびｔｎｆ媒介性疾患を処置する方法
EP3594230A1 (en) *	2013-02-13	2020-01-15	Laboratoire Français du Fractionnement et des Biotechnologies	Highly galactosylated anti-tnf-alpha antibodies and uses thereof
HK1207960A1 (en)	2013-03-12	2016-02-19	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
BR112015017307A2 (pt)	2013-03-14	2017-11-21	Abbvie Inc	composições de espécies com baixa acidez e métodos para produção e uso das mesmas
MX362075B (es)	2013-03-14	2019-01-07	Abbott Lab	Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
WO2014159579A1 (en) *	2013-03-14	2014-10-02	Abbvie Inc.	MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014143343A1 (en)	2013-03-14	2014-09-18	Abbott Laboratories	Hcv core lipid binding domain monoclonal antibodies
US20140275082A1 (en)	2013-03-14	2014-09-18	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2016512241A (ja)	2013-03-14	2016-04-25	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
CA2899449A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	Low acidic species compositions and methods for producing the same using displacement chromatography
WO2014144280A2 (en)	2013-03-15	2014-09-18	Abbvie Inc.	DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
CN105209491A (zh)	2013-03-15	2015-12-30	艾伯维公司	针对TNFα的双重特异性结合蛋白
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
US10150800B2 (en)	2013-03-15	2018-12-11	Zyngenia, Inc.	EGFR-binding modular recognition domains
JP2016520595A (ja) *	2013-05-22	2016-07-14	メタボリックエンジニアリングラボラトリーズカンパニーリミテッド	抗ＴＮＦ−α／ＣＸＣＬ１０二重ターゲット抗体及びその用途
US10183988B2 (en)	2013-06-07	2019-01-22	Duke University	Anti-Complement factor H antibodies
WO2015006555A2 (en)	2013-07-10	2015-01-15	Sutro Biopharma, Inc.	Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015017683A1 (en) *	2013-07-31	2015-02-05	Malast Mary	Antimicrobial compositions and methods of use
RU2016107435A (ru)	2013-09-13	2017-10-18	Дженентек, Инк.	Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CN120904322A (zh)	2013-09-13	2025-11-07	豪夫迈·罗氏有限公司	包含纯化的重组多肽的方法和组合物
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CA2926644A1 (en)	2013-10-06	2015-04-09	Abbvie Inc.	Dual specific binding proteins directed against immune cell receptors and autoantigens
EP3055298B1 (en)	2013-10-11	2020-04-29	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3057616B1 (en)	2013-10-16	2020-03-11	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
CA2931978A1 (en)	2013-12-02	2015-06-11	Abbvie Inc.	Compositions and methods for treating osteoarthritis
CN103965357B (zh)	2013-12-31	2016-08-17	嘉和生物药业有限公司	一种抗人rankl抗体
EP3110976B1 (en)	2014-02-27	2020-05-13	Biogen MA Inc.	Method of assessing risk of pml
PL3116891T3 (pl)	2014-03-10	2020-07-27	Richter Gedeon Nyrt.	Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
AR099812A1 (es)	2014-03-21	2016-08-17	Abbvie Inc	Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
AR099625A1 (es) *	2014-03-21	2016-08-03	Lilly Co Eli	Anticuerpos de il-21
WO2015151115A1 (en) *	2014-04-02	2015-10-08	Intas Pharmaceuticals Limited	Liquid pharmaceutical composition of adalimumab
US11052132B2 (en)	2014-05-08	2021-07-06	Phasebio Pharmaceuticals, Inc.	Methods and compositions for treating cystic fibrosis
EP2946767B1 (en)	2014-05-23	2016-10-05	Ares Trading S.A.	Liquid pharmaceutical composition
ES2572919T3 (es)	2014-05-23	2016-06-03	Ares Trading S.A.	Composición farmacéutica líquida
PT2946765T (pt)	2014-05-23	2016-11-10	Ares Trading Sa	Composição farmacêutica líquida
FR3022462B1 (fr) *	2014-06-18	2018-04-27	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Composition orale d'anticorps anti-tnfalpha
WO2015198320A1 (en)	2014-06-24	2015-12-30	Insight Biopharmaceuticals Ltd.	Methods of purifying antibodies
CA2953714C (en) *	2014-06-30	2021-05-18	Ralf Guenther	Anti-tnfa antibodies with ph-dependent antigen binding
WO2016004197A1 (en)	2014-07-03	2016-01-07	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en)	2014-07-09	2016-01-14	Abbvie Inc.	Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
US10755801B2 (en)	2014-07-11	2020-08-25	Iogenetics, Llc	Identifying peptides having T-cell-exposed motifs with known frequency of occurrence in a reference database
EA202193002A2 (ru)	2014-09-03	2022-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Соединение, нацеленное на ил-23a и фно-альфа, и его применение
US10435464B1 (en)	2014-09-05	2019-10-08	Coherus Biosciences, Inc.	Methods for making recombinant proteins
HUP1400510A1 (hu)	2014-10-28	2016-05-30	Richter Gedeon Nyrt	Gyógyászati TNFalfa ellenes antitest készítmény
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
EP3237000A1 (en)	2014-12-23	2017-11-01	Pfizer Inc	Stable aqueous antibody formulation for anti tnf alpha antibodies
EP3085709B1 (en)	2014-12-28	2019-08-21	Genor Biopharma Co., Ltd	Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
WO2016118707A1 (en)	2015-01-21	2016-07-28	Oncobiologics, Inc.	Modulation of charge variants in a monoclonal antibody composition
EP3053572A1 (en)	2015-02-06	2016-08-10	Ares Trading S.A.	Liquid pharmaceutical composition
CN114652817B (zh)	2015-02-09	2026-04-17	费斯生物制药公司	用于治疗肌肉疾病和病症的方法和组合物
CN105777905B (zh) *	2015-03-24	2019-06-25	广东东阳光药业有限公司	一种全人源抗TNF-α单克隆抗体及其应用
EP3078675A1 (en)	2015-04-10	2016-10-12	Ares Trading S.A.	Induction dosing regimen for the treatment of tnf alpha mediated disorders
WO2016179469A1 (en) *	2015-05-07	2016-11-10	Abbvie Inc.	Methods and compositions for diagnosing and treating inflammatory bowel disease
CN107810198B (zh)	2015-05-29	2021-09-03	艾伯维公司	抗cd40抗体及其用途
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
FR3038517B1 (fr)	2015-07-06	2020-02-28	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Utilisation de fragments fc modifies en immunotherapie
HU231463B1 (hu)	2015-08-04	2024-01-28	Richter Gedeon Nyrt.	Módszer rekombináns proteinek galaktóz tartalmának növelésére
US11229702B1 (en)	2015-10-28	2022-01-25	Coherus Biosciences, Inc.	High concentration formulations of adalimumab
US11583584B1 (en)	2015-10-28	2023-02-21	Coherus Biosciences, Inc.	Stable protein compositions and methods of their use
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
CN109563161A (zh)	2016-02-03	2019-04-02	安口生物公司	用于提高抗体稳定性的缓冲制剂
US10465003B2 (en)	2016-02-05	2019-11-05	Janssen Biotech, Inc.	Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
US10774140B2 (en)	2016-03-17	2020-09-15	Numab Therapeutics AG	Anti-TNFα-antibodies and functional fragments thereof
DK3219726T3 (da) *	2016-03-17	2020-12-07	Tillotts Pharma Ag	Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
EP3440113A1 (en)	2016-04-08	2019-02-13	Gilead Sciences, Inc.	Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US11071782B2 (en)	2016-04-20	2021-07-27	Coherus Biosciences, Inc.	Method of filling a container with no headspace
JP6871948B2 (ja)	2016-04-27	2021-05-19	アッヴィ・インコーポレイテッド	抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
US20180126000A1 (en)	2016-06-02	2018-05-10	Abbvie Inc.	Glucocorticoid receptor agonist and immunoconjugates thereof
AU2017277534A1 (en)	2016-06-08	2019-01-03	Abbvie Inc.	Anti-EGFR antibody drug conjugates
AU2017279550A1 (en)	2016-06-08	2019-01-03	Abbvie Inc.	Anti-B7-H3 antibodies and antibody drug conjugates
BR112018075639A2 (pt)	2016-06-08	2019-04-09	Abbvie Inc.	conjugados de anticorpo fármaco anti-egfr
WO2017214322A1 (en)	2016-06-08	2017-12-14	Abbvie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates
JP2019524651A (ja)	2016-06-08	2019-09-05	アッヴィ・インコーポレイテッド	抗ｃｄ９８抗体及び抗体薬物コンジュゲート
MX2018015285A (es)	2016-06-08	2019-09-18	Abbvie Inc	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
WO2017218698A1 (en)	2016-06-15	2017-12-21	Sutro Biopharma, Inc.	Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
WO2018018613A1 (zh)	2016-07-29	2018-02-01	广东东阳光药业有限公司	一种提高抗体纯度的细胞培养基和培养方法
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
WO2018045258A1 (en) *	2016-09-02	2018-03-08	The University Of Chicago	TREATMENT OF TNF-alpha CYTOTOXICITY
JP2020501508A (ja) *	2016-09-15	2020-01-23	クアドルセプトバイオリミテッド	多量体、四量体および八量体
CN110383068A (zh)	2016-10-03	2019-10-25	雅培实验室	评估患者样品中uch-l1状态的改进方法
WO2018075408A1 (en)	2016-10-17	2018-04-26	Alexion Pharmaceuticals, Inc.	Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
PT3528787T (pt)	2016-10-21	2026-03-11	Amgen Inc	Formulações farmacêuticas e métodos para produzir as mesmas
WO2018102594A1 (en)	2016-12-01	2018-06-07	Alexion Pharmaceuticals, Inc.	Methods of treating solid tumors with anti-cd200 antibodies
WO2018106945A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
CN110430801B (zh)	2016-12-14	2024-04-30	比奥拉治疗股份有限公司	使用tnf抑制剂治疗胃肠道疾病
EP3554544A4 (en)	2016-12-16	2020-07-29	Bluefin Biomedicine, Inc.	ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
WO2018119142A1 (en)	2016-12-21	2018-06-28	Amgen Inc.	Anti-tnf alpha antibody formulations
JOP20190162A1 (ar)	2016-12-30	2019-06-27	Biocad Joint Stock Co	تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
ES2933808T3 (es) *	2017-01-11	2023-02-14	Celltrion Inc	Fórmula líquida estable
TWI787230B (zh)	2017-01-20	2022-12-21	法商賽諾菲公司	抗ＴＧＦ-β抗體及其用途
TWI832600B (zh)	2017-01-20	2024-02-11	美商健臻公司	骨靶向抗體
WO2018140121A1 (en)	2017-01-30	2018-08-02	Janssen Biotech, Inc.	Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
MX2019009377A (es)	2017-02-07	2019-12-11	Janssen Biotech Inc	Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
US11608357B2 (en)	2018-08-28	2023-03-21	Arecor Limited	Stabilized antibody protein solutions
EP3372242A1 (en)	2017-03-06	2018-09-12	Ares Trading S.A.	Liquid pharmaceutical composition
EP3372241A1 (en)	2017-03-06	2018-09-12	Ares Trading S.A.	Liquid pharmaceutical composition
CA3261113A1 (en)	2017-03-23	2025-10-27	Abbott Laboratories	Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
CN110382052A (zh)	2017-03-26	2019-10-25	Mapi医药公司	用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2018184692A1 (en)	2017-04-07	2018-10-11	Ares Trading S.A.	Liquid pharmaceutical composition
WO2018191531A1 (en)	2017-04-15	2018-10-18	Abbott Laboratories	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
US10866251B2 (en)	2017-05-25	2020-12-15	Abbott Laboratories	Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
JP7269182B2 (ja)	2017-05-30	2023-05-08	アボット・ラボラトリーズ	心臓トロポニンｉ及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
US11169159B2 (en)	2017-07-03	2021-11-09	Abbott Laboratories	Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
US11761963B2 (en)	2017-09-27	2023-09-19	Alexion Pharmaceuticals, Inc.	Biomarker signature for predicting tumor response to anti-CD200 therapy
BR112020010694A2 (pt)	2017-12-01	2020-11-10	Abbvie Inc.	agonista de receptor de glicocorticoides e imunoconjugados do mesmo
CN109879962B (zh) *	2017-12-06	2022-10-11	北京科立思维生物科技有限公司	抗tnf单链抗体、抗il-6单链抗体及其融合蛋白及其应用
JP7379165B2 (ja)	2017-12-09	2023-11-14	アボット・ラボラトリーズ	Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
EP3721233A2 (en)	2017-12-09	2020-10-14	Abbott Laboratories	Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019126133A1 (en)	2017-12-20	2019-06-27	Alexion Pharmaceuticals, Inc.	Liquid formulations of anti-cd200 antibodies
WO2019126536A1 (en)	2017-12-20	2019-06-27	Alexion Pharmaceuticals Inc.	Humanized anti-cd200 antibodies and uses thereof
BR112020017701A2 (pt)	2018-03-12	2020-12-29	Zoetis Services Llc	Anticorpos anti-ngf e métodos dos mesmos
WO2019190877A1 (en)	2018-03-26	2019-10-03	Alexion Pharmaceuticals, Inc.	High throughput method for measuring the protease activity of complement c3 convertase
CN119080931A (zh)	2018-06-04	2024-12-06	马萨诸塞州渤健公司	具有降低的效应功能的抗vla-4抗体
US20230312700A1 (en)	2018-06-20	2023-10-05	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN112654350A (zh)	2018-07-03	2021-04-13	诺华股份有限公司	使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
CN113329769A (zh)	2018-10-11	2021-08-31	斯克里普斯研究学院	具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
US20220387397A1 (en)	2018-10-24	2022-12-08	Novartis Ag	Compounds and compositions for treating conditions associated with nlrp activity
JP7682788B2 (ja) *	2018-11-05	2025-05-26	北京韓美薬品有限公司	抗ＴＮＦα／抗ＩＬ－１７Ａ天然抗体構造様ヘテロダイマー二重特異性抗体及びその製造方法
HU231514B1 (hu)	2018-11-07	2024-07-28	Richter Gedeon Nyrt.	Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
EP3880666B1 (en)	2018-11-13	2023-06-28	Novartis AG	Compounds and compositions for treating conditions associated with nlrp activity
CN113015730A (zh)	2018-11-13	2021-06-22	诺华股份有限公司	用于治疗与nlrp活性相关的病症的化合物和组合物
EP3883635A1 (en)	2018-11-19	2021-09-29	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
WO2020118011A1 (en)	2018-12-06	2020-06-11	Alexion Pharmaceuticals, Inc.	Anti-alk2 antibodies and uses thereof
ES3031988T3 (en)	2018-12-25	2025-07-14	Beijing Baishihekang Pharmaceutical Tech Bsjpharma Co Ltd	Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
EP3914583A1 (en)	2019-01-22	2021-12-01	Novartis AG	Compounds and compositions for treating conditions associated with nlrp activity
HU231498B1 (hu)	2019-04-04	2024-05-28	Richter Gedeon Nyrt	Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
KR102323342B1 (ko)	2019-04-26	2021-11-08	주식회사 와이바이오로직스	IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
JP7805788B2 (ja)	2019-05-23	2026-01-26	ヤンセンバイオテツク，インコーポレーテツド	Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
WO2021002887A1 (en)	2019-07-02	2021-01-07	Novartis Inflammasome Research, Inc.	Gut-targeted nlrp3 antagonists and their use in therapy
WO2021005607A1 (en) *	2019-07-09	2021-01-14	National Institute For Biotechnology In The Negev Ltd.	Antibodies with reduced immunogenicity
CN115666704B (zh)	2019-12-13	2025-09-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
FR3104582A1 (fr)	2019-12-17	2021-06-18	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Variants de l’adalimumab au potentiel immunogène réduit
KR20220137698A (ko)	2020-02-05	2022-10-12	라리마 테라퓨틱스, 인코포레이티드	Tat 펩티드 결합 단백질 및 이의 용도
US20230095053A1 (en)	2020-03-03	2023-03-30	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
EP4136459A1 (en)	2020-04-13	2023-02-22	Abbott Laboratories	Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
IL298389A (en)	2020-05-21	2023-01-01	Janssen Biotech Inc	Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3188349A1 (en)	2020-08-04	2022-02-10	A. Scott Muerhoff	Improved methods and kits for detecting sars-cov-2 protein in a sample
CN111944052B (zh) *	2020-08-26	2022-02-11	中国药科大学	抗TNF-α/PD-1双特异性抗体及其应用
CN116601173A (zh)	2020-09-11	2023-08-15	阿雷克森制药公司	抗铜蓝蛋白抗体及其用途
CN112010970B (zh) *	2020-10-30	2021-01-12	迈威(上海)生物科技股份有限公司	一种去除重组表达抗体聚体和降解产物的方法
WO2023102384A1 (en)	2021-11-30	2023-06-08	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
US20220170948A1 (en)	2020-12-01	2022-06-02	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
US11672929B2 (en)	2020-12-02	2023-06-13	Breathe Restore, Inc.	Product delivery devices and methods
WO2022123293A1 (ko)	2020-12-09	2022-06-16	에이치케이이노엔 주식회사	항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
KR20230154300A (ko) *	2020-12-18	2023-11-07	킨드레드 바이오사이언시스, 인코포레이티드	수의학용 tnf 알파 및 ngf 항체
EP4271998A1 (en)	2020-12-30	2023-11-08	Abbott Laboratories	Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
JP2024507220A (ja)	2021-02-19	2024-02-16	セリピオン，インコーポレイテッド	パラオキソナーゼ融合ポリペプチドならびに関連する組成物および方法
US20240216535A1 (en)	2021-04-27	2024-07-04	Generation Bio Co.	Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
AU2022264509A1 (en)	2021-04-27	2023-12-14	Generation Bio Co.	Non-viral dna vectors expressing therapeutic antibodies and uses thereof
US20220381796A1 (en)	2021-05-18	2022-12-01	Abbott Laboratories	Methods of evaluating brain injury in a pediatric subject
WO2022266034A1 (en)	2021-06-14	2022-12-22	Abbott Laboratories	Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
AU2022298665A1 (en) *	2021-06-22	2024-01-04	University Of Virginia Patent Foundation	Compositions and methods for detecting and regulating fibronectin-integrin interactions and signaling
CN120463762A (zh)	2021-08-26	2025-08-12	映恩生物科技(上海)有限公司	一种甾体化合物及其缀合物
CN118715440A (zh)	2021-08-31	2024-09-27	雅培实验室	诊断脑损伤的方法和系统
JP2024534849A (ja)	2021-08-31	2024-09-26	アボット・ラボラトリーズ	脳の損傷を診断する方法及びシステム
JP2024538608A (ja)	2021-09-30	2024-10-23	アボット・ラボラトリーズ	脳の損傷を診断する方法及びシステム
EP4448179A1 (en)	2021-12-17	2024-10-23	Abbott Laboratories	Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023150652A1 (en)	2022-02-04	2023-08-10	Abbott Laboratories	Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
CN119072330A (zh)	2022-03-14	2024-12-03	世代生物公司	异源初免加强疫苗组合物和使用方法
JP2025526279A (ja) *	2022-06-28	2025-08-13	アダフレ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニー	抗ＴＮＦα抗体および組成物
CN120167040A (zh)	2022-06-29	2025-06-17	雅培实验室	用于确定生物样本中的gfap的磁性定点照护型系统和测定
CN116903738A (zh) *	2022-08-02	2023-10-20	北京绿竹生物技术股份有限公司	一种低甘露糖型抗人肿瘤坏死因子-α单抗及其用途
IL319437A (en)	2022-09-07	2025-05-01	Mdx Man Llc	Shp-1 inhibitors for treating cancer
JP2025532597A (ja)	2022-09-15	2025-10-01	アボット・ラボラトリーズ	軽度及び超軽度の外傷性脳損傷を区別するためのバイオマーカー及び方法
WO2024097804A1 (en)	2022-11-02	2024-05-10	Mdx Management Llc	Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
AU2024239074A1 (en)	2023-03-17	2025-10-02	Mdx Management Llc	Compositions and methods for ameliorating adverse effects of therapies
WO2024211475A1 (en)	2023-04-04	2024-10-10	Abbott Laboratories	Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
EP4713682A1 (en)	2023-04-28	2026-03-25	Abbott Point of Care Inc.	Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2025038745A1 (en)	2023-08-16	2025-02-20	Mdx Management Llc	Compositions and methods for activating immune cells
WO2025188920A1 (en)	2024-03-06	2025-09-12	Mdx Management Llc	Local application of agents inhibiting tyrosine kinase or shp-1 signaling
WO2025238106A1 (en)	2024-05-15	2025-11-20	M6P Therapeutics (Switzerland) GmbH	Lysosome-targeting degradation fusion design
WO2026043823A2 (en)	2024-08-19	2026-02-26	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026080697A1 (en)	2024-10-09	2026-04-16	Sutro Biopharma, Inc.	Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4680276A (en) *	1977-05-25	1987-07-14	Institut National De La Sante Et De La Recherche Medicale	Metal polypeptides
JPS58501544A (ja)	1981-09-08	1983-09-16	ザ　ロツクフエラ−　ユニヴア−シテイ	エンドトキシン誘発メディエ−タ−（ショック検定）によるリポプロティンリパ−ゼの抑圧
US5672347A (en)	1984-07-05	1997-09-30	Genentech, Inc.	Tumor necrosis factor antagonists and their use
IL73883A (en)	1984-12-20	1990-12-23	Yeda Res & Dev	Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US4661016A (en) *	1985-04-11	1987-04-28	Mobil Oil Corporation	Subsea flowline connector
EP0613006A1 (en)	1985-08-16	1994-08-31	The Rockefeller University	Antibodies to cachectin and immunoassays
DE3631229A1 (de)	1986-09-13	1988-03-24	Basf Ag	Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
GB8630273D0 (en) *	1986-12-18	1987-01-28	Til Medical Ltd	Pharmaceutical delivery systems
NZ229922A (en)	1988-07-18	1992-04-28	Chiron Corp	Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
GB8823869D0 (en) *	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US4940723A (en) *	1988-10-20	1990-07-10	University Of North Carolina, Chapel Hill	Use of bis-(5-amidino-2-benzimidazolyl) methane (BABIM) to treat arthritis
DE68914244T2 (de)	1988-10-24	1994-10-27	Otsuka Pharma Co Ltd	Monoklonaler Antikörper.
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IE63847B1 (en) *	1989-05-05	1995-06-14	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
DE3918082A1 (de) *	1989-06-02	1991-01-24	Max Planck Gesellschaft	Mittel gegen autoimmunerkrankungen
US5959087A (en) *	1989-08-07	1999-09-28	Peptide Technology, Ltd.	Tumour necrosis factor binding ligands
US6451983B2 (en)	1989-08-07	2002-09-17	Peptech Limited	Tumor necrosis factor antibodies
JP3443119B2 (ja)	1989-08-07	2003-09-02	ペプテックリミテッド	腫瘍壊死因子結合リガンド
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6673986B1 (en) *	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6150584A (en) *	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US7084260B1 (en) *	1996-10-10	2006-08-01	Genpharm International, Inc.	High affinity human antibodies and human antibodies against human antigens
US6255458B1 (en) *	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
US5545806A (en) *	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) *	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) *	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6300129B1 (en) *	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) *	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) *	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) *	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
GB9022547D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Purified immunoglobulin
US5994510A (en)	1990-12-21	1999-11-30	Celltech Therapeutics Limited	Recombinant antibodies specific for TNFα
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
GB2279077B (en) *	1990-12-21	1995-06-14	Celltech Ltd	Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
GB9028123D0 (en)	1990-12-28	1991-02-13	Erba Carlo Spa	Monoclonal antibodies against human tumor necrosis factor alpha
US20070298040A1 (en)	1991-03-18	2007-12-27	Centocor, Inc.	Methods of treating seronegative arthropathy with anti-TNF antibodies
US6277969B1 (en)	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
US20060246073A1 (en)	1991-03-18	2006-11-02	Knight David M	Anti-TNF antibodies and peptides of human tumor necrosis factor
EP1857553A1 (en) *	1991-03-18	2007-11-21	New York University	Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US5698195A (en) *	1991-03-18	1997-12-16	New York University Medical Center	Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) *	1991-03-18	1997-08-12	New York University Medical Center	Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US20040120952A1 (en)	2000-08-07	2004-06-24	Centocor, Inc	Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) *	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US5328985A (en) *	1991-07-12	1994-07-12	The Regents Of The University Of California	Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
EP0605522B1 (en)	1991-09-23	1999-06-23	Medical Research Council	Methods for the production of humanized antibodies
WO1994026910A1 (en)	1993-05-12	1994-11-24	Xoma Corporation	Immunotoxins comprising gelonin and an antibody
US5869619A (en) *	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
US6270766B1 (en)	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
CA2146647C (en) *	1992-10-08	2009-05-05	Marc Feldmann	Treatment of autoimmune and inflammatory disorders
DE69427928T3 (de) *	1993-03-05	2012-05-10	Bayer Healthcare Llc	Humane monoklonale anti-TNF alpha Antikörper
ATE183513T1 (de)	1993-06-03	1999-09-15	Therapeutic Antibodies Inc	Herstellung von antikörperfragmenten
WO1995011317A1 (en)	1993-10-19	1995-04-27	The Scripps Research Institute	Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0659766A1 (en)	1993-11-23	1995-06-28	Schering-Plough	Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
JPH09509835A (ja)	1994-03-04	1997-10-07	メルクエンドカンパニーインコーポレーテッド	アラニン走査型突然変異誘発によるｉｎｖｉｔｒｏ抗体アフィニティー成熟
JPH07289288A (ja) *	1994-04-27	1995-11-07	L T T Kenkyusho:Kk	抗リウマチ薬の効果評価方法
JPH10503179A (ja)	1994-06-24	1998-03-24	イミュネックス・コーポレーション	放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
US5561053A (en)	1994-08-05	1996-10-01	Genentech, Inc.	Method for selecting high-expressing host cells
GB9416721D0 (en) *	1994-08-18	1994-10-12	Short Brothers Plc	A bias yarn assembly forming device
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6090382A (en) *	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
MX336813B (es)	1996-02-09	2016-02-02	Abbvie Biotechnology Ltd	Anticuerpos humanos que ligan el tnfa humano.
WO2000058362A1 (en) *	1999-03-26	2000-10-05	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
US20060018907A1 (en)	2000-08-07	2006-01-26	Centocor, Inc.	Anti-TNF antibodies and peptides of human tumor necrosis factor
US20050249735A1 (en)	2000-08-07	2005-11-10	Centocor, Inc.	Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20030012786A1 (en)	2001-05-25	2003-01-16	Teoh Leah S.	Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
CA2817619A1 (en) *	2001-06-08	2002-12-08	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
US20030161828A1 (en)	2002-02-19	2003-08-28	Abbott Gmbh & Co. Kg	Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US20040009172A1 (en)	2002-04-26	2004-01-15	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
US20090280065A1 (en) *	2006-04-10	2009-11-12	Willian Mary K	Uses and Compositions for Treatment of Psoriasis
WO2004009776A2 (en)	2002-07-19	2004-01-29	Abbott Biotechnology Ltd.	TREATMENT OF TNFα RELATED DISORDERS
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
US20040054414A1 (en) *	2002-09-18	2004-03-18	Trieu Hai H.	Collagen-based materials and methods for augmenting intervertebral discs
MY150740A (en)	2002-10-24	2014-02-28	Abbvie Biotechnology Ltd	Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) *	2004-04-09	2017-02-16	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2006041970A2 (en)	2004-10-08	2006-04-20	Abbott Biotechnology Ltd.	Treatment of respiratory syncytial virus (rsv) infection
NZ595225A (en)	2005-05-16	2013-05-31	Abbott Biotech Ltd	Use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en)	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
CN103336129A (zh)	2005-11-01	2013-10-02	阿布维生物技术有限公司	使用生物标志物诊断强直性脊柱炎的方法和组合物
CN102887955A (zh) *	2006-04-05	2013-01-23	艾博特生物技术有限公司	抗体纯化
WO2007120626A2 (en) *	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Uses and compositions for treatment of ankylosing spondylitis
WO2008063213A2 (en) *	2006-04-10	2008-05-29	Abbott Biotechnology Ltd.	Uses and compositions for treatment of psoriatic arthritis
US20090317399A1 (en) *	2006-04-10	2009-12-24	Pollack Paul F	Uses and compositions for treatment of CROHN'S disease
US9399061B2 (en) *	2006-04-10	2016-07-26	Abbvie Biotechnology Ltd	Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20080118496A1 (en)	2006-04-10	2008-05-22	Medich John R	Uses and compositions for treatment of juvenile rheumatoid arthritis
US9605064B2 (en) *	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
US20080131374A1 (en) *	2006-04-19	2008-06-05	Medich John R	Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) *	2006-06-08	2010-01-28	Wong Robert L	Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en)	2006-06-08	2008-12-18	Hoffman Rebecca S	Uses and compositions for treatment of psoriatic arthritis
MX2008016335A (es) *	2006-06-30	2009-01-21	Abbott Biotech Ltd	Dispositivo automatico de inyeccion.
AU2007294731B2 (en)	2006-09-13	2014-04-17	Abbvie Inc.	Cell culture improvements
ES2442258T3 (es) *	2006-10-27	2014-02-10	Abbvie Biotechnology Ltd	Anticuerpos cristalinos anti-hTNF alfa
RU2476442C2 (ru)	2007-03-29	2013-02-27	Эббот Лэборетриз	Кристаллические антитела против il-12 человека
WO2008150491A2 (en)	2007-05-31	2008-12-11	Abbott Laboratories	BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
EP2152318A4 (en) *	2007-06-01	2011-12-07	Abbott Biotech Ltd	COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
WO2008154543A2 (en) *	2007-06-11	2008-12-18	Abbott Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis
JP2010533181A (ja) *	2007-07-13	2010-10-21	アボツト・バイオテクノロジー・リミテツド	ＴＮＦα阻害剤の肺投与のための方法及び組成物
WO2009020654A1 (en) *	2007-08-08	2009-02-12	Abbott Laboratories	Compositions and methods for crystallizing antibodies
US8420081B2 (en) *	2007-11-30	2013-04-16	Abbvie, Inc.	Antibody formulations and methods of making same
US20090271164A1 (en) *	2008-01-03	2009-10-29	Peng Joanna Z	Predicting long-term efficacy of a compound in the treatment of psoriasis
CA2711984A1 (en) *	2008-01-15	2009-07-23	Abbott Gmbh & Co. Kg	Powdered protein compositions and methods of making same
TWI478937B (zh) *	2008-01-15	2015-04-01	Abbvie Inc	改良之哺乳動物表現載體及其用途
CN102065892A (zh)	2008-01-30	2011-05-18	雅培制药有限公司	用于使抗体片段结晶的组合物和方法
JP2011517672A (ja) *	2008-03-24	2011-06-16	アボツト・バイオテクノロジー・リミテツド	骨損失を治療するための方法及び組成物
WO2010127146A1 (en)	2009-04-29	2010-11-04	Abbott Biotechnology Ltd	Automatic injection device
US20100278822A1 (en) *	2009-05-04	2010-11-04	Abbott Biotechnology, Ltd.	Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
JP2013518590A (ja)	2010-02-02	2013-05-23	アボツト・バイオテクノロジー・リミテツド	ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
EP2575884B1 (en)	2010-06-03	2018-07-18	AbbVie Biotechnology Ltd	Uses and compositions for treatment of hidradenitis suppurativa (hs)
US9085618B2 (en) *	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same

1997
- 1997-02-10 MX MX2012010598A patent/MX336813B/es unknown
- 1997-02-10 PT PT97906572T patent/PT929578E/pt unknown
- 1997-02-10 AU AU21229/97A patent/AU722077B2/en not_active Expired
- 1997-02-10 NZ NZ576716A patent/NZ576716A/en not_active IP Right Cessation
- 1997-02-10 DE DE200412000003 patent/DE122004000003I1/de active Pending
- 1997-02-10 DE DE1997621548 patent/DE122004000003I2/de active Active
- 1997-02-10 DE DE200412000004 patent/DE122004000004I1/de active Pending
- 1997-02-10 NZ NZ562935A patent/NZ562935A/en not_active IP Right Cessation
- 1997-02-10 RO ROA200500050A patent/RO123028B1/ro unknown
- 1997-02-10 DK DK97906572T patent/DK0929578T3/da active
- 1997-02-10 HU HU1500179A patent/HU230515B1/hu unknown
- 1997-02-10 SK SK1062-98A patent/SK284040B6/sk not_active IP Right Cessation
- 1997-02-10 RU RU2003120859/15A patent/RU2270030C2/ru active
- 1997-02-10 TR TR1998/01532T patent/TR199801532T2/xx unknown
- 1997-02-10 CN CN2010105525099A patent/CN102070715A/zh active Pending
- 1997-02-10 KR KR1019980706163A patent/KR100317188B1/ko not_active Expired - Lifetime
- 1997-02-10 EP EP97906572A patent/EP0929578B1/en not_active Expired - Lifetime
- 1997-02-10 PL PL97328411A patent/PL188192B1/pl unknown
- 1997-02-10 HU HU0204115A patent/HU228630B1/hu unknown
- 1997-02-10 CN CN200910225399A patent/CN101712720A/zh active Pending
- 1997-02-10 NZ NZ331579A patent/NZ331579A/xx not_active IP Right Cessation
- 1997-02-10 CN CNB031009581A patent/CN100429232C/zh not_active Expired - Lifetime
- 1997-02-10 NZ NZ512006A patent/NZ512006A/en not_active IP Right Cessation
- 1997-02-10 BR BRPI9707379-2A patent/BRPI9707379B8/pt active IP Right Grant
- 1997-02-10 BR BRPI9715219-6A patent/BRPI9715219B8/pt active IP Right Grant
- 1997-02-10 CZ CZ19982476A patent/CZ292465B6/cs not_active IP Right Cessation
- 1997-02-10 CN CN201310141436.8A patent/CN103275221B/zh not_active Expired - Lifetime
- 1997-02-10 US US09/125,098 patent/US6258562B1/en not_active Expired - Lifetime
- 1997-02-10 HU HU1300152A patent/HU230048B1/hu unknown
- 1997-02-10 SI SI9720020A patent/SI9720020B/sl unknown
- 1997-02-10 RO RO98-01269A patent/RO119831B1/ro unknown
- 1997-02-10 HU HU9901874A patent/HU221984B1/hu active IP Right Grant
- 1997-02-10 IL IL12569797A patent/IL125697A/xx not_active IP Right Cessation
- 1997-02-10 CN CNB971936358A patent/CN1300173C/zh not_active Expired - Lifetime
- 1997-02-10 ES ES97906572T patent/ES2198552T3/es not_active Expired - Lifetime
- 1997-02-10 WO PCT/US1997/002219 patent/WO1997029131A1/en not_active Ceased
- 1997-02-10 DE DE69721548T patent/DE69721548T2/de not_active Expired - Lifetime
- 1997-02-10 CA CA002243459A patent/CA2243459C/en not_active Expired - Lifetime
- 1997-02-10 JP JP52875597A patent/JP3861118B2/ja not_active Expired - Lifetime
- 1997-02-10 NZ NZ536216A patent/NZ536216A/en not_active IP Right Cessation
- 1997-02-10 BR BRPI9707379A patent/BRPI9707379C8/pt unknown
- 1997-02-10 AT AT97906572T patent/ATE239041T1/de active
- 1997-02-10 PL PL97365237A patent/PL193499B1/pl unknown
- 1997-10-02 UA UA98094737A patent/UA57726C2/uk unknown
1998
- 1998-08-07 NO NO19983627A patent/NO316711B1/no not_active IP Right Cessation
- 1998-09-08 BG BG107537A patent/BG64776B1/bg unknown
- 1998-09-08 BG BG102755A patent/BG64564B1/bg unknown
- 1998-09-08 BG BG107537/2003A patent/BG107537A/xx unknown
2000
- 2000-01-01 BG BG109311A patent/BG109311A/en unknown
2001
- 2001-03-07 US US09/801,185 patent/US7223394B2/en not_active Expired - Fee Related
2002
- 2002-09-04 JP JP2002259017A patent/JP4404181B2/ja not_active Expired - Lifetime
- 2002-09-05 IL IL15164102A patent/IL151641A0/xx active Protection Beyond IP Right Term
- 2002-09-30 UA UA2002097761A patent/UA82823C2/uk unknown
- 2002-12-23 NO NO20026202A patent/NO319955B1/no not_active IP Right Cessation
2004
- 2004-01-07 NO NO20040052A patent/NO322755B1/no not_active IP Right Cessation
- 2004-01-13 NO NO20040154A patent/NO320657B1/no not_active IP Right Cessation
- 2004-02-25 LU LU91062C patent/LU91062I2/fr unknown
- 2004-02-27 NL NL300143C patent/NL300143I2/nl unknown
- 2004-04-15 NO NO2004002C patent/NO2004002I2/no unknown
- 2004-06-24 CY CY0400052A patent/CY2463B1/xx unknown
2005
- 2005-05-11 RU RU2005113954/15A patent/RU2458704C9/ru not_active Application Discontinuation
- 2005-09-30 BG BG109311A patent/BG66195B1/bg unknown
- 2005-11-24 CY CY2005011C patent/CY2005011I1/el unknown
2006
- 2006-08-17 JP JP2006222629A patent/JP4890997B2/ja not_active Expired - Lifetime
2007
- 2007-04-17 US US11/787,901 patent/US7541031B2/en not_active Expired - Fee Related
2009
- 2009-02-11 US US12/369,451 patent/US8206714B2/en not_active Expired - Fee Related
- 2009-10-13 US US12/578,487 patent/US8372400B2/en not_active Expired - Fee Related
2010
- 2010-06-30 JP JP2010149053A patent/JP5422501B2/ja not_active Expired - Lifetime
- 2010-07-12 BG BG110703A patent/BG66509B1/bg unknown
- 2010-07-14 IL IL206994A patent/IL206994A0/en unknown
2012
- 2012-01-24 RU RU2012102323/10A patent/RU2012102323A/ru not_active Application Discontinuation
- 2012-03-07 IL IL218518A patent/IL218518A0/en unknown
- 2012-06-15 US US13/524,525 patent/US8753633B2/en not_active Expired - Fee Related
2013
- 2013-01-08 US US13/736,931 patent/US20130115224A1/en not_active Abandoned
- 2013-02-06 JP JP2013021012A patent/JP5689902B2/ja not_active Expired - Lifetime
- 2013-08-12 US US13/965,152 patent/US20130330356A1/en not_active Abandoned
- 2013-08-12 US US13/965,155 patent/US20130330357A1/en not_active Abandoned
- 2013-11-01 JP JP2013228008A patent/JP5759526B2/ja not_active Expired - Lifetime
2015
- 2015-02-13 JP JP2015026021A patent/JP5951056B2/ja not_active Expired - Lifetime
- 2015-06-24 BG BG112042A patent/BG112042A/bg unknown
2016
- 2016-02-10 JP JP2016023326A patent/JP2016104798A/ja active Pending
- 2016-03-04 HK HK16102509.2A patent/HK1214609A1/en unknown
- 2016-03-04 HK HK16102512.7A patent/HK1214610A1/en unknown
- 2016-03-04 HK HK16102500.1A patent/HK1214608A1/en unknown
- 2016-03-04 HK HK16102499.4A patent/HK1214607A1/en unknown
2017
- 2017-08-01 NO NO2017038C patent/NO2017038I2/no unknown

Also Published As

Publication number	Publication date
RU2458704C2 (ru)	2012-08-20
JP2013091666A (ja)	2013-05-16
MX9806347A (es)	1998-10-31
BG107537A (bg)	2003-09-30
CN103275221A (zh)	2013-09-04
NO20026202D0 (no)	2002-12-23
HK1214607A1 (en)	2016-07-29
HK1214610A1 (en)	2016-07-29
BR9715219B1 (pt)	2010-02-23
CN1504752A (zh)	2004-06-16
SK106298A3 (en)	1999-03-12
CY2005011I1 (el)	2011-06-08
NO20040052L (no)	1998-10-07
DK0929578T3 (da)	2003-08-25
US20130330356A1 (en)	2013-12-12
BR9707379B1 (pt)	2009-08-11
SI9720020A (sl)	1999-10-31
JP4404181B2 (ja)	2010-01-27
HU230515B1 (hu)	2016-10-28
US8206714B2 (en)	2012-06-26
HU228630B1 (en)	2013-04-29
BRPI9707379B8 (pt)	2015-07-07
US20030092059A1 (en)	2003-05-15
BRPI9707379C8 (pt)	2017-12-12
JP2007045828A (ja)	2007-02-22
IL125697A (en)	2005-03-20
CN100429232C (zh)	2008-10-29
KR19990082430A (ko)	1999-11-25
PT929578E (pt)	2003-09-30
JP5951056B2 (ja)	2016-07-13
US20120258114A1 (en)	2012-10-11
ATE239041T1 (de)	2003-05-15
RU2005113954A (ru)	2006-11-20
NO319955B1 (no)	2005-10-03
HU230048B1 (hu)	2015-06-29
NO2017038I1 (no)	2017-08-01
BG64564B1 (bg)	2005-07-29
NO983627D0 (no)	1998-08-07
HU221984B1 (hu)	2003-03-28
NZ331579A (en)	2001-06-29
DE69721548T2 (de)	2004-04-01
BG66509B1 (bg)	2015-11-30
CA2243459A1 (en)	1997-08-14
SK284040B6 (sk)	2004-08-03
IL125697A0 (en)	1999-04-11
HK1125972A1 (en)	2009-08-21
JP5689902B2 (ja)	2015-03-25
NZ576716A (en)	2011-02-25
HK1066860A1 (en)	2005-04-01
IL218518A0 (en)	2012-04-30
NZ512006A (en)	2005-05-27
IL151641A0 (en)	2003-04-10
MX336813B (es)	2016-02-02
PL328411A1 (en)	1999-01-18
CA2243459C (en)	2002-09-17
HUP1500179A2 (en)	1999-09-28
NO983627L (no)	1998-10-07
BG112042A (bg)	2015-10-30
LU91062I2 (fr)	2004-04-26
CY2463B1 (en)	2005-06-03
BG64776B1 (bg)	2006-03-31
CZ247698A3 (cs)	1998-11-11
CN103275221B (zh)	2016-08-17
US20130115224A1 (en)	2013-05-09
NO2004002I2 (no)	2008-02-04
BG110703A (en)	2010-10-29
JP2014055150A (ja)	2014-03-27
RU2012102323A (ru)	2013-07-27
NO2017038I2 (no)	2017-11-17
DE122004000003I1 (de)	2004-09-23
RU2458704C9 (ru)	2012-12-10
PL188192B1 (pl)	2004-12-31
RU2003120859A (ru)	2005-01-10
CN1300173C (zh)	2007-02-14
HK1125951A1 (en)	2009-08-21
NL300143I1 (nl)	2004-05-03
NZ536216A (en)	2006-08-31
US20090155205A1 (en)	2009-06-18
NO316711B1 (no)	2004-04-13
HUP9901874A2 (hu)	1999-09-28
AU2122997A (en)	1997-08-28
US8753633B2 (en)	2014-06-17
RU2270030C2 (ru)	2006-02-20
TR199801532T2 (xx)	1998-11-23
BRPI9715219B8 (pt)	2015-07-07
UA82823C2 (en)	2008-05-26
DE69721548D1 (de)	2003-06-05
NO20026202L (no)	1998-10-07
DE122004000003I2 (de)	2007-03-29
NO322755B1 (no)	2006-12-04
KR100317188B1 (ko)	2002-02-19
JP2016104798A (ja)	2016-06-09
CN102070715A (zh)	2011-05-25
NO320657B1 (no)	2006-01-09
BG102755A (en)	1999-05-31
US6258562B1 (en)	2001-07-10
HU0204115D0 (en)	2003-02-28
US20130330357A1 (en)	2013-12-12
US8372400B2 (en)	2013-02-12
NZ562935A (en)	2009-06-26
JP2003177130A (ja)	2003-06-27
US20100040604A1 (en)	2010-02-18
JP5759526B2 (ja)	2015-08-05
PL193499B1 (pl)	2007-02-28
WO1997029131A1 (en)	1997-08-14
EP0929578B1 (en)	2003-05-02
RO123028B1 (ro)	2010-07-30
HK1019452A1 (en)	2000-02-11
JP3861118B2 (ja)	2006-12-20
AU722077B2 (en)	2000-07-20
CN1215407A (zh)	1999-04-28
BG66195B1 (bg)	2012-01-31
US7223394B2 (en)	2007-05-29
HK1214608A1 (en)	2016-07-29
JP5422501B2 (ja)	2014-02-19
BG109311A (en)	2006-03-31
JP2000507810A (ja)	2000-06-27
NL300143I2 (nl)	2004-07-01
JP4890997B2 (ja)	2012-03-07
UA57726C2 (uk)	2003-07-15
RO119831B1 (ro)	2005-04-29
EP0929578A1 (en)	1999-07-21
IL206994A0 (en)	2010-12-30
HUP9901874A3 (en)	2000-05-29
JP2015108011A (ja)	2015-06-11
US7541031B2 (en)	2009-06-02
CN101712720A (zh)	2010-05-26
NO20040154L (no)	1998-10-07
CZ292465B6 (cs)	2003-09-17
US20070249813A1 (en)	2007-10-25
JP2010209119A (ja)	2010-09-24
ES2198552T3 (es)	2004-02-01
DE122004000004I1 (de)	2004-08-12
BR9707379A (pt)	1999-04-13
HK1214609A1 (en)	2016-07-29

Legal Events

Date	Code	Title	Description
2005-01-10	IF	Valid on the event date
2005-04-30	SP73	Change of data on owner	Owner name: ABBOTT BIOTECHNOLOGY LTD.; BM Effective date: 20050310
2006-04-30	SPCF	Application for supplementary protection certificate filed	Free format text: PRODUCT NAME: ADALIMUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/03/257/001-006; DATE OF NATIONAL AUTHORISATION: 20040501; AUTHORITY FOR NATIONAL AUTHORISATION: EU; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 56221 01; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20030416; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: CH Spc suppl protection certif: 200440031 Filing date: 20041028
2006-10-31	SPCG	Supplementary protection certificate granted	Free format text: PRODUCT NAME: ADALIMUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/03/257/001-006; DATE OF NATIONAL AUTHORISATION: 20040501; AUTHORITY FOR NATIONAL AUTHORISATION: EU; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 56221 01; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20030416; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: CH Spc suppl protection certif: 200440031 Filing date: 20041028 Expiry date: 20170210 Extension date: 20180416
2014-05-30	SP73	Change of data on owner	Owner name: ABBVIE BIOTECHNOLOGY LTD.; BM Effective date: 20140408
2014-05-30	SPC1	Supplementary protection certificate: data on owner changed or corrected	Free format text: PRODUCT NAME: ADALIMUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/03/257/001-006; DATE OF NATIONAL AUTHORISATION: 20040501; AUTHORITY FOR NATIONAL AUTHORISATION: EU; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 56221 01; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20030416; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: CH Spc suppl protection certif: 200440031 Filing date: 20041028
2015-07-31	SPCE	Application for extension of supplementary protection certificate filed	Free format text: PRODUCT NAME: ADALIMUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/03/257/001-006; DATE OF NATIONAL AUTHORISATION: 20040501; AUTHORITY FOR NATIONAL AUTHORISATION: EU; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 56221 01; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20030416; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: CH Spc suppl protection certif: 200440031 Filing date: 20041028
2015-09-30	SPCZ	Supplementary protection certificate extension granted	Free format text: PRODUCT NAME: ADALIMUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/03/257/001-006; DATE OF NATIONAL AUTHORISATION: 20040501; AUTHORITY FOR NATIONAL AUTHORISATION: EU; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 56221 01; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20030416; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: CH Spc suppl protection certif: 200440031 Filing date: 20041028 Expiry date: 20170210 Extension date: 20181016

Publication	Publication Date	Title
SI9720020B (en)	2001-12-31	Human antibodies that bind human TNF alpha
JP2021006044A (ja)	2021-01-21	腫瘍壊死因子（ｔｎｆ）スーパーファミリー受容体結合分子およびその使用
JP2022105108A5 (cs)	2022-11-10
CN102439040B (zh)	2017-05-03	抗TNF‑α抗体和其用途
JP5534819B2 (ja)	2014-07-02	ｈｕＴＮＦＲ１選択的拮抗剤
RU2009128064A (ru)	2011-01-27	Антитела к cd44
US10052382B2 (en)	2018-08-21	Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides
WO2012058588A4 (en)	2012-12-06	Novel egfr-binding molecules and immunoconjugates thereof
RU2011116927A (ru)	2012-11-10	Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2014507138A5 (cs)	2017-03-09
WO1996022384A1 (en)	1996-07-25	Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
RU2009126766A (ru)	2011-01-20	Антитела человека к дельта-подобному лиганду-4 человека
CA3064298A1 (en)	2018-12-06	Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CN116940598A (zh)	2023-10-24	用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
CN101111521B (zh)	2011-08-24	肿瘤坏死因子-α特异性人源化抗体
CN117924497A (zh)	2024-04-26	一种靶向bcma的纳米抗体及其应用
JP2010514413A5 (cs)	2011-02-10
CN121758618A (zh)	2026-03-31	Pd1和vegfr2双结合剂
JP2024516098A5 (cs)	2025-03-18
TWI906795B (zh)	2025-12-01	特異性結合Ｃｌａｕｄｉｎ１８.２的抗體及其製法和應用
WO2001079494A1 (fr)	2001-10-25	Anticorps agonistes
JP2024546939A5 (cs)	2025-07-07
US12139530B2 (en)	2024-11-12	Bispecific antibody specifically binding to IL-17A and TNF-α
KR102048475B1 (ko)	2019-11-26	IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
JP2018510150A (ja)	2018-04-12	Ｊａｇ１に結合する抗体医薬